CareDx, Inc Q3 2025 Earnings Recap

CDNA Q3 2025 November 5, 2025

Get alerts when CDNA reports next quarter

CareDx reported robust third-quarter 2025 results with total revenue reaching $100.1 million, marking a 21% year-over-year growth, driven by strong performance across its testing services and product offerings.

Earnings Per Share Beat

$0.28 vs $0.13 est.

+115.4% surprise

Revenue Miss

100055000 vs 102756000 est.

-2.6% surprise

Market Reaction

1-Day +13.84%

5-Day +15.01%

30-Day +23.07%

See CDNA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Testing Services revenue reached $72.2 million, a 19% increase year-over-year, with a total of approximately 50,300 tests delivered.
Adjusted EBITDA surged to $15.3 million, more than doubling from the same quarter last year.
The company has raised its 2025 revenue guidance to $372-$376 million and adjusted EBITDA guidance to $35-$39 million.
CareDx announced the launch of HistoMap Kidney, a breakthrough tissue-based molecular test aimed at improving diagnostic precision in transplant care.
Share repurchases accelerated, with 2 million shares bought back at an average price of $12.87, totaling approximately 9% repurchased year-to-date.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CDNA on AllInvestView.

Next Q1 2026